866-997-4948(US-Canada Toll Free)

Metastatic Transitional (Urothelial) Tract Cancer Global Clinical Trials Review, H2, 2017

Published By :

GlobalData

Published Date : Dec 2017

Category :

Pharmaceutical

No. of Pages : 155 Pages

Metastatic Transitional (Urothelial) Tract Cancer Global Clinical Trials Review, H2, 2017

Summary

GlobalData's clinical trial report, Metastatic Transitional (Urothelial) Tract Cancer Global Clinical Trials Review, H2, 2017" provides an overview of Metastatic Transitional (Urothelial) Tract Cancer clinical trials scenario. This report provides top line data relating to the clinical trials on Metastatic Transitional (Urothelial) Tract Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalDatas proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
GlobalData Clinical Trials Report Coverage 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Five Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Metastatic Transitional (Urothelial) Tract Cancer to Oncology Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Metastatic Transitional (Urothelial) Tract Cancer to Oncology Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Subjects Recruited Over a Period of Time 25
Clinical Trials by Sponsor Type 26
Prominent Sponsors 27
Top Companies Participating in Metastatic Transitional (Urothelial) Tract Cancer Therapeutics Clinical Trials 28
Prominent Drugs 29
Latest Clinical Trials News on Metastatic Transitional (Urothelial) Tract Cancer 30
Nov 08, 2017: Astellas and Seattle Genetics Initiate Phase 1b Trial of Enfortumab Vedotin in Combination with Immune Checkpoint Inhibitor Therapies in Locally Advanced or Metastatic Urothelial Cancer 30
Oct 10, 2017: Astellas and Seattle Genetics Initiate Pivotal Trial of Enfortumab Vedotin for Patients with Locally Advanced or Metastatic Urothelial Cancer 30
Clinical Trial Profile Snapshots 31
Appendix 152
Abbreviations 152
Definitions 152
Research Methodology 153
Secondary Research 153
About GlobalData 154
Contact Us 154
Disclaimer 154
Source 155

List of Tables
Metastatic Transitional (Urothelial) Tract Cancer Therapeutics, Global, Clinical Trials by Region, 2017* 7
Metastatic Transitional (Urothelial) Tract Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 8
Metastatic Transitional (Urothelial) Tract Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 9
Metastatic Transitional (Urothelial) Tract Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017* 10
Metastatic Transitional (Urothelial) Tract Cancer Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 11
Metastatic Transitional (Urothelial) Tract Cancer Therapeutics Clinical Trials, North America, Top Countries, 2017* 12
Metastatic Transitional (Urothelial) Tract Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2017* 13
Metastatic Transitional (Urothelial) Tract Cancer Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2017* 14
Proportion of Metastatic Transitional (Urothelial) Tract Cancer to Oncology Clinical Trials, G7 Countries (%), 2017* 15
Metastatic Transitional (Urothelial) Tract Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 16
Metastatic Transitional (Urothelial) Tract Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 17
Proportion of Metastatic Transitional (Urothelial) Tract Cancer to Oncology Clinical Trials, E7 Countries (%), 2017* 18
Metastatic Transitional (Urothelial) Tract Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 19
Metastatic Transitional (Urothelial) Tract Cancer Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 20
Metastatic Transitional (Urothelial) Tract Cancer Therapeutics, Global, Clinical Trials by Phase, 2017* 21
Metastatic Transitional (Urothelial) Tract Cancer Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 22
Metastatic Transitional (Urothelial) Tract Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2017* 23
Metastatic Transitional (Urothelial) Tract Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2017* 24
Metastatic Transitional (Urothelial) Tract Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 25
Metastatic Transitional (Urothelial) Tract Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 26
Metastatic Transitional (Urothelial) Tract Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 27
Metastatic Transitional (Urothelial) Tract Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 28
Metastatic Transitional (Urothelial) Tract Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 29

List of Figures
Metastatic Transitional (Urothelial) Tract Cancer Therapeutics, Global, Clinical Trials by Region (%), 2017* 7
Metastatic Transitional (Urothelial) Tract Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 8
Metastatic Transitional (Urothelial) Tract Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 9
Metastatic Transitional (Urothelial) Tract Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017* 10
Metastatic Transitional (Urothelial) Tract Cancer Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017* 11
Metastatic Transitional (Urothelial) Tract Cancer Therapeutics Clinical Trials, North America, Top Countries (%), 2017* 12
Metastatic Transitional (Urothelial) Tract Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2017* 13
Metastatic Transitional (Urothelial) Tract Cancer Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2017* 14
Proportion of Metastatic Transitional (Urothelial) Tract Cancer to Oncology Clinical Trials, G7 Countries (%), 2017* 15
Metastatic Transitional (Urothelial) Tract Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 16
Metastatic Transitional (Urothelial) Tract Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 17
Proportion of Metastatic Transitional (Urothelial) Tract Cancer to Oncology Clinical Trials, E7 Countries (%), 2017* 18
Metastatic Transitional (Urothelial) Tract Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 19
Metastatic Transitional (Urothelial) Tract Cancer Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 20
Metastatic Transitional (Urothelial) Tract Cancer Therapeutics, Global, Clinical Trials by Phase (%), 2017* 21
Metastatic Transitional (Urothelial) Tract Cancer Therapeutics, Global, Clinical Trials In Progress by Phase, 2017* 22
Metastatic Transitional (Urothelial) Tract Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2017* 23
Metastatic Transitional (Urothelial) Tract Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2017* 24
Metastatic Transitional (Urothelial) Tract Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 25
Metastatic Transitional (Urothelial) Tract Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017* 26
Metastatic Transitional (Urothelial) Tract Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 27
Metastatic Transitional (Urothelial) Tract Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 28
Metastatic Transitional (Urothelial) Tract Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 29
GlobalData Methodology 153

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *